SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of earliest event reported): |
February 21, 2003 |
BioMarin Pharmaceutical Inc.
(Exact name of registrant as specified in its charter)
| Delaware |
000-26727 |
68-0397820 | ||
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 371 Bel Marin Keys Boulevard, Suite 210, Novato, California |
94949 | |
| (Address of principal executive offices) |
(Zip Code) |
| Registrant’s telephone number, including area code: |
(415) 884-6700 |
Not Applicable
(Former name or former address, if changed since last report)
Item 5. Other Events.
On February 21, 2003, BioMarin Pharmaceutical Inc. (the “Registrant”), together with its joint venture partner Genzyme General, issued a press release regarding the issuance by the Committee for Proprietary Medicinal Products (CPMP) of the European Union of a positive opinion on the companies’ marketing application for Aldurazyme. The Registrant’s press release issued on February 21, 2003 is attached hereto as Exhibit 99.1.
Item 7. Financial Statements, Pro Forma Financial Statements and Exhibits.
| (a) | Financial Statements of Business Acquired. |
Not Applicable.
| (b) | Pro Forma Financial Information. |
Not Applicable.
| (c) | Exhibits. |
| Exhibit 99.1 |
Press Release of the Registrant dated February 21, 2003. |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BioMarin Pharmaceutical Inc., a Delaware corporation | ||||
| Date: February 21, 2003 |
By: |
/s/ LOUIS DRAPEAU | ||
| Louis Drapeau Chief Financial Officer | ||||
EXHIBIT INDEX
| Exhibit No. |
Description | |
| Exhibit 99.1 |
Press Release of the Registrant dated February 21, 2003. |
3